Show simple item record

dc.contributor.authorMbuagbaw, L
dc.contributor.authorGuglielmetti, L
dc.contributor.authorHewison, C
dc.contributor.authorBakare, N
dc.contributor.authorBastard, M
dc.contributor.authorCaumes, E
dc.contributor.authorFrechet-Jachym, M
dc.contributor.authorRobert, J
dc.contributor.authorVeziris, N
dc.contributor.authorKhachatryan, N
dc.contributor.authorKotrikadze, T
dc.contributor.authorHayrapetyan, A
dc.contributor.authorAvaliani, Z
dc.contributor.authorSchünemann, HJ
dc.contributor.authorLienhardt, C
dc.date.accessioned2019-06-25T15:06:52Z
dc.date.available2019-06-25T15:06:52Z
dc.date.issued2019-05-01
dc.date.submitted2019-05-03
dc.identifier.issn1080-6059
dc.identifier.pmid31002070
dc.identifier.doi10.3201/eid2505.181823
dc.identifier.urihttp://hdl.handle.net/10144/619395
dc.description.abstractBedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%-81.9%), and the treatment success rate was 65.8% (95% CI 59.9%-71.3%). Death rate was 11.7% (95% CI 7.0%-19.1%). Up to 91.1% (95% CI 82.2%-95.8%) of the patients experienced >1 adverse event, and 11.2% (95% CI 5.0%-23.2%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low.en_US
dc.language.isoenen_US
dc.publisherCenters for Disease Control and Preventionen_US
dc.rightsWith thanks to the Centers for Disease Control and Prevention.en_US
dc.subjectArmenia
dc.subjectAsia
dc.subjectChina
dc.subjectEurope
dc.subjectFrance
dc.subjectGeorgia
dc.subjectMDR
dc.subjectSouth Africa
dc.subjectTB
dc.subjectXDR
dc.subjectantimicrobial resistance
dc.subjectbacteria
dc.subjectbedaquiline
dc.subjectextensively drug resistant
dc.subjectindividual patient data
dc.subjectmultidrug resistant
dc.subjecttuberculosis
dc.subjecttuberculosis and other mycobacteria
dc.titleOutcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosisen_US
dc.identifier.journalEmerging Infectious Diseasesen_US
dc.source.journaltitleEmerging infectious diseases
refterms.dateFOA2019-06-25T15:06:52Z


Files in this item

Thumbnail
Name:
Mbuagbaw et al - 2019 - Outcomes ...
Size:
1.246Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record